// App-Quantinova.ai

LB 01.4 : Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

Researchers

Presenter

  • A. von Drygalski

Principal Investigators

  • P. Chowdary

  • R. Kulkarni

  • S. Susen

  • B. Konkle

  • J. Oldenburg

  • D. Matino

  • R. Klamroth

  • A. Weyand

  • V. Jimenez Yuste

  • K. Nogami

  • S. Poloskey

  • B. Winding

  • A. Willemze

  • K. Knobe

Medical Centers

  • Division of Gastroenterology, Dept of Medicine, University of California, San Diego, San Diego, California, United States

  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK

  • Michigan State University, East Lansing, MI, United States

  • Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, Nord-Pas-de-Calais, France

  • Washington Center for Bleeding Disorders and the University of Washington, Seattle, Washington, United States

  • Institute of Experimental Hematology and Transfusion Medicine and Centre for Rare Diseases, Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany

  • Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Canada

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • Division of Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbour, Michigan, United States

  • Hospital Universitario La Paz, Autonoma University, Madrid, Spain

  • Nara Medical University, Kashihara, Japan

  • STC Biologics, Cambridge, Massachusetts, United States

  • Sobi, Stockholm, Stockholms Lan, Sweden

  • Sanofi, Amsterdam, Noord-Holland, Netherlands

  • Sanofi,Chilly-Mazarin, Ile-de-France,France

Locations

  • United States

  • United Kingdom

  • France

  • Germany

  • Canada

  • Spain

  • Japan

  • Sweden

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Observational

Phase

  • III

Study Id's

  • NCT04161495

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved